

(19)



(11)

EP 2 404 616 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
29.02.2012 Bulletin 2012/09

(51) Int Cl.:
A61K 39/395 (2006.01) C07K 16/22 (2006.01)
C12N 15/09 (2006.01)

(43) Date of publication A2:
11.01.2012 Bulletin 2012/02

(21) Application number: **11175663.1**

(22) Date of filing: **08.12.2006**

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR MK RS

(72) Inventors:
• **Cartlidge, Susan Ann**
Macclesfield
Cheshire SK10 4TG (GB)
• **Tonge, David William**
Macclesfield
Cheshire SK10 4TG (GB)
• **Raeber, Olivia**
Redwood City
California 94061 (US)
• **Gazit-Bornstein, Gadi**
Cambridge
Massachusetts 02141 (US)
• **Yang, Xiaodong**
Palo Alto
California 94306 (US)

(30) Priority: **13.12.2005 US 750085 P**
14.12.2005 US 750772 P
17.02.2006 US 774747 P
24.05.2006 US 808183 P

(83) **Declaration under Rule 32(1) EPC (expert solution)**

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
06848597.8 / 1 979 001

(74) Representative: **Bates, Rosica Florence**
MedImmune Ltd.
Milstein Building
Granta Park
Cambridge CB21 6GH (GB)

(71) Applicant: **AstraZeneca AB**
151 85 Södertälje (SE)

(54) Binding proteins specific for insulin-like growth factors and uses thereof

(57) Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.

3T3 Clone 32 Efficacy Study Tumor Growth Curve (All mice alive)




FIG. 1

EP 2 404 616 A3



EUROPEAN SEARCH REPORT

Application Number
EP 11 17 5663

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	WO 2005/018671 A (KYOWA HAKKO KOGYO KK [JP]; JAPAN GOVERNMENT [JP]; OCHIAI ATSUSHI [JP];) 3 March 2005 (2005-03-03) * the whole document *	1-16	INV. A61K39/395 C07K16/22 C12N15/09
X,P	& EP 1 661 582 A (KYOWA HAKKO KOGYO KK [JP]; JAPAN GOVERNMENT [JP]) 31 May 2006 (2006-05-31) * (Engl. language equivalent of WO2005/018671) Whole document, in particular p.6 *	1-16	
X	EP 1 505 075 A1 (KYOWA HAKKO KOGYO KK [JP]) 9 February 2005 (2005-02-09) * the whole document *	1-16	
A	WO 2005/016970 A (IMCLONE SYSTEMS INC [US]; LUDWIG DALE L [US]) 24 February 2005 (2005-02-24) * the whole document *	1-16	
A	GOYA MASATO ET AL: "Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 64, no. 17, 2004, pages 6252-6258, XP002982679, ISSN: 0008-5472 * the whole document *	1-16	TECHNICAL FIELDS SEARCHED (IPC) A61K C07K
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 4 January 2012	Examiner Roscoe, Richard
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

1
EPO FORM 1503 03 02 (F04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 11 17 5663

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	RUSSEL W E ET AL: "Inhibition of the mitogenic effects of plasma by a monoclonal antibody to somatomedin C", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 81, no. 8, 1984, pages 2389-2392, XP002984258, ISSN: 0027-8424 * the whole document * -----	1-16	TECHNICAL FIELDS SEARCHED (IPC)
A	VAN WUK JUDSON J ET AL: "Molecular basis for species and ligand specificity of a monoclonal antibody raised against human IGF-I", ENDOCRINOLOGY, vol. 138, no. 10, 1997, pages 4521-4522, XP002438459, ISSN: 0013-7227 * the whole document * -----	1-16	
A	MIYAMOTO SHIN'ICHI ET AL: "Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 11, no. 9, 1 May 2005 (2005-05-01), pages 3494-3502, XP002414392, ISSN: 1078-0432 * the whole document * ----- -/--	1-16	
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 4 January 2012	Examiner Roscoe, Richard
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

1
EPO FORM 1503 03.02 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 11 17 5663

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	ENJOH T ET AL: "Characterization of new monoclonal antibodies to human insulin-like growth factor-II and their application in Western immunoblot analysis", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, ENDOCRINE SOCIETY, CHEVY CHASE, MD, US, vol. 77, no. 2, 1993, pages 510-517, XP002971827, ISSN: 0021-972X * the whole document * -----	1-16	
A	MANES S ET AL: "FUNCTIONAL EPITOPE MAPPING OF INSULIN-LIKE GROWTH FACTOR I (IGF-I) BY ANTI-IGF-I MONOCLONAL ANTIBODIES", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 138, no. 3, 1997, pages 905-915, XP002918936, ISSN: 0013-7227 * the whole document * -----	1-16	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (IPC)
Place of search Munich		Date of completion of the search 4 January 2012	Examiner Roscoe, Richard
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

1
EPO FORM 1503 03/02 (P04001)

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 11 17 5663

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

04-01-2012

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2005018671 A	03-03-2005	CA 2536288 A1	03-03-2005
		EP 1661582 A1	31-05-2006
		US 2006263362 A1	23-11-2006
		WO 2005018671 A1	03-03-2005

EP 1505075 A1	09-02-2005	AT 444972 T	15-10-2009
		AU 2003231554 A1	17-11-2003
		CA 2483848 A1	13-11-2003
		EP 1505075 A1	09-02-2005
		ES 2333952 T3	03-03-2010
		JP 4335130 B2	30-09-2009
		US 2006165695 A1	27-07-2006
		WO 03093317 A1	13-11-2003

WO 2005016970 A	24-02-2005	CA 2524305 A1	24-02-2005
		EP 1622942 A2	08-02-2006
		EP 2365001 A2	14-09-2011
		JP 2007535895 A	13-12-2007
		JP 2011184440 A	22-09-2011
		US 2008025990 A1	31-01-2008
		US 2010158920 A1	24-06-2010
WO 2005016970 A2	24-02-2005		
